Organon & Co.

Headquarters: Jersey City, NJ, United States

Employees: 9,500

CEO: Mr. Kevin Ali

NYSE: OGN +1.30%

Market Cap

$3.74 Billion

USD as of Jan. 1, 2024

Market Cap History

Organon & Co. market capitalization over time

Evolution of Organon & Co. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Organon & Co.

Detailed Description

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Organon & Co. has the following listings and related stock indices.

Stock: NYSE: OGN wb_incandescent

Stock: FSX: 7XP wb_incandescent



30 Hudson Street

Jersey City, NJ 07302

United States

Phone: 551 430 6000